Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant

Objectives: The aim of the present study was to evaluate if neutralizing antibody responses induced by infection with the SARS-CoV-2 strain that was dominant at the beginning of the pandemic or by the Gamma variant was effective against the Omicron variant. Methods: Convalescent sera from 109 individuals, never exposed to a SARS-CoV-2 vaccine, who had mild or moderate symptoms not requiring hospitalization following either a documented SARS-CoV-2 ancestral strain infection or a Gamma variant infection, were assayed for in vitro neutralizing antibody activity against their original strains and the Omicron variant. Results: Following an infection with the ancestral strain, 56 (93.3%), 45 (77.6%) and 1 (1.7%) serum sample were positive for neutralizing antibodies against the ancestral, Gamma variant, and Omicron variant, respectively. After infection with the Gamma variant, 43 (87.8%) and 2 (4.1%) sera were positive for neutralizing antibodies against the Gamma and Omicron variants, respectively. Conclusions: Neutralizing antibodies generated following mild or moderate infection with the SARS-CoV-2 ancestral strain or the Gamma variant are not protective against the Omicron variant.

Palavras-chave

SARS-CoV-2, Omicron variant, Gamma variant, Neutralizing antibodies, Protective antibodies

URI

https://observatorio.fm.usp.br/handle/OPI/49242

Referências

Aine OToole J.T., PANGOLIN COVID 19 LI
Boehm E, 2021, CLIN MICROBIOL INFEC, V27, P1109, DOI 10.1016/j.cmi.2021.05.022
Brasil. Ministerio da Saude. Fundacao Oswaldo Cruz, DASHB GEN NETW
Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude, B EP ESP DOENC PEIO
Cao Y, 2021, NUMER LINEAR ALGEBR, V28, DOI [10.1002/nla.2362, 10.1038/s41586-021-04385-3]
Cromer D, 2021, NAT REV IMMUNOL, V21, P395, DOI 10.1038/s41577-021-00550-x
de Jesus JG, 2020, REV INST MED TROP SP, V62, DOI [10.1590/S1678-9946202062030, 10.1590/s1678-9946202062030]
Dejnirattisai W, 2021, CELL, V184, P2939, DOI 10.1016/j.cell.2021.03.055
Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1101/2021.02.26.21252554, 10.1126/science.abh2644Article]
Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.04.006, 10.1016/j.cell.2021.03.013]
Hierholzer J. C., 1996, P25, DOI 10.1016/B978-012465330-6/50003-8
Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036
Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
Kellam P, 2020, J GEN VIROL, V101, P791, DOI 10.1099/jgv.0.001439
Khoshkam Z, 2021, J ADV RES, V31, P49, DOI 10.1016/j.jare.2020.12.013
Lau EHY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20247-4
Leal FE, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-042745
Li MC, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392-022-00880-9
Mendrone A, 2021, TRANSFUSION, V61, P1181, DOI 10.1111/trf.16268
Neter J, 1996, APPL LINEAR STAT MOD
Nurtop E, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1105-5
Planas D, 2022, NATURE, V602, P671, DOI 10.1038/s41586-021-04389-z
Rodda LB, 2021, CELL, V184, P169, DOI [10.1016/j.cell.2020.11.029, 10.1101/2020.08.11.20171843, 10.21203/rs.3.rs-57112/v1]
Roltgen K, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0240
Schmidt F, 2022, NEW ENGL J MED, V386, P599, DOI 10.1056/NEJMc2119641
Wendel S, 2020, TRANSFUSION, V60, P2938, DOI 10.1111/trf.16065

Coleções

Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/46

Carregar mais

Página do item completo